Cisplatine 1 mg/ml PCH

DRUG2 trials

Sponsors

Gilead Sciences Inc., Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Conditions

Advanced Non-Small Cell Lung CancerTriple negative breast cancer (TNBC) with metastatic disease

Phase 2

A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer

Active, not recruitingCTIS2022-502916-35-01

Gilead Sciences Inc.Advanced Non-Small Cell Lung Cancer

Start: 2024-03-27Target: 171Updated: 2025-09-10

Immune induction strategies to improve response to immune checkpoint blockade in triple negative breast cancer (TNBC) patients: the TONIC-2 trial

Active, not recruitingCTIS2024-513217-12-00

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingTriple negative breast cancer (TNBC) with metastatic disease

Start: 2020-02-04Target: 34Updated: 2025-01-13